Artelon is a technology company.
Artelon has raised $20.0M across 1 funding round.
Artelon has raised $20.0M in total across 1 funding round.
Artelon is a medtech company that develops bio-textiles, particularly its FLEXBAND technology, for dynamic augmentation in tendon and ligament reconstruction.[1][2][4][5] It serves orthopedic surgeons and patients with injuries in foot and ankle, sports medicine, and soft tissue repair, solving the problem of failed synthetic implants by providing a degradable, elastic material that reinforces healing tissues, restores motion, and integrates biologically over 4-6 years with over 60,000 implantations worldwide.[2][3][4][5] Founded in 2013 in Atlanta, Georgia, Artelon raised $20M from investors like Vensana Capital before being acquired by Stryker in June 2024, enhancing Stryker's offerings in soft tissue fixation.[1][3]
Artelon's origins trace to orthopedic surgeon Lars Peterson, MD/PhD, whose clinical experience with failing synthetic tendon and ligament devices inspired a new material design.[2] Collaborating with chemists and textile engineers, Peterson developed the Dynamic Matrix—the foundation of FLEXBAND—a patented co-polymer of polycaprolactone and polyurethane-urea knitted into a porous textile for soft tissue integration.[2][4] Launched in 2013 and headquartered in Sandy Springs, GA, the company gained early traction through its focus on joint stability, culminating in over 60,000 global implantations and acquisition by Stryker in 2024.[1][2][3]
Artelon rides the wave of advanced biomaterials in orthopedics, addressing limitations of traditional grafts amid rising sports injuries and aging populations demanding faster, motion-preserving recoveries.[2][3][4] Its timing aligns with medtech consolidation, as seen in Stryker's 2024 acquisitions (e.g., Artelon, OrthoGrid, care.ai), fueling growth in foot/ankle and sports medicine segments valued for minimally invasive, regenerative solutions.[1][3] By influencing Stryker's ecosystem, Artelon accelerates adoption of dynamic textiles, setting standards for bio-integration that could expand to broader soft tissue repairs and shape competitive biomaterials R&D.[3]
Post-acquisition, Artelon will integrate into Stryker's Trauma & Extremities division, likely expanding FLEXBAND applications via Stryker's global reach and R&D, targeting more procedures in sports medicine and beyond.[3] Trends like AI-guided orthopedics and personalized implants will amplify its role, with its proven track record positioning it to lead in elastic, degradable tech amid demand for "active stability."[1][3][4] Expect evolved influence through scaled implantations and procedure innovations, reinforcing Artelon's legacy from Peterson's vision to a Stryker powerhouse in restoring natural motion.[2][3]
Artelon has raised $20.0M in total across 1 funding round.
Artelon's investors include Vensana Capital.
Artelon has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series B in May 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2023 | $20.0M Series B | Vensana Capital |